The FDA has completed its review of the investigational new drug application (IND) for PSV359, and issued a "study may proceed” letter in 1Q 2025. Site activation activities are underway, with the ...
R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback